In the past week, TCRX stock has gone down by -8.75%, with a monthly gain of 17.74% and a quarterly plunge of -14.12%. The volatility ratio for the week is 2.65%, and the volatility levels for the last 30 days are 6.04% for Tscan Therapeutics Inc The simple moving average for the last 20 days is -6.23% for TCRX stock, with a simple moving average of -52.42% for the last 200 days.
Is It Worth Investing in Tscan Therapeutics Inc (NASDAQ: TCRX) Right Now?
Company’s 36-month beta value is 0.98.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TCRX is 43.83M, and currently, short sellers hold a 4.60% ratio of that floaft. The average trading volume of TCRX on June 20, 2025 was 577.92K shares.
TCRX) stock’s latest price update
Tscan Therapeutics Inc (NASDAQ: TCRX) has seen a decline in its stock price by -5.19 in relation to its previous close of 1.54. However, the company has experienced a -8.75% decline in its stock price over the last five trading sessions. https://www.defenseworld.net reported 2025-06-11 that Squarepoint Ops LLC purchased a new position in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 19,461 shares of the company’s stock, valued at approximately $59,000. A number of other large investors also recently bought and sold shares of the stock. SG Americas Securities LLC raised its stake in TScan Therapeutics by 31.2% during the fourth quarter. SG Americas Securities LLC now owns 20,415 shares of the company’s stock worth $62,000 after purchasing an additional 4,852 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of TScan Therapeutics by 41.1% during the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock valued at $59,000 after acquiring an additional 5,694 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of TScan Therapeutics by 5.2% during the 4th quarter. Wellington Management Group LLP now owns 132,895 shares of the company’s stock valued at $404,000 after acquiring an additional 6,550 shares in the last quarter. Barclays PLC lifted its holdings in shares of TScan Therapeutics by 16.3% during the 4th quarter. Barclays PLC now owns 67,508 shares of the company’s stock valued at $206,000 after acquiring an additional 9,441 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new position in shares of TScan Therapeutics during the 4th quarter valued at $32,000. Hedge funds and other institutional investors own 82.83% of the company’s stock. TScan Therapeutics Price Performance TCRX opened at $1.69 on Wednesday. The company has a 50-day moving average of $1.43 and a 200-day moving average of $2.18. The company has a market capitalization of $95.64 million, a P/E ratio of -1.59 and a beta of 0.98. TScan Therapeutics, Inc. has a 1-year low of $1.02 and a 1-year high of $9.29. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56. TScan Therapeutics (NASDAQ:TCRX – Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The business had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.62 million. Equities analysts expect that TScan Therapeutics, Inc. will post -1.12 EPS for the current fiscal year. Analysts Set New Price Targets TCRX has been the topic of several recent research reports. HC Wainwright reduced their target price on shares of TScan Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Wedbush restated an “outperform” rating and set a $7.00 target price on shares of TScan Therapeutics in a report on Tuesday, May 6th. Needham & Company LLC restated a “buy” rating and set a $9.00 target price on shares of TScan Therapeutics in a report on Tuesday, April 8th. Barclays reduced their target price on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $10.00 price target on shares of TScan Therapeutics in a research note on Friday, March 14th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $7.80. View Our Latest Research Report on TCRX Insider Activity at TScan Therapeutics In other news, major shareholder Lynx1 Capital Management Lp bought 1,200,000 shares of TScan Therapeutics stock in a transaction on Tuesday, May 20th. The stock was purchased at an average cost of $1.20 per share, with a total value of $1,440,000.00. Following the purchase, the insider now directly owns 7,946,141 shares of the company’s stock, valued at approximately $9,535,369.20. This trade represents a 17.79% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 4.35% of the company’s stock. TScan Therapeutics Profile (Free Report) TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.
Analysts’ Opinion of TCRX
Many brokerage firms have already submitted their reports for TCRX stocks, with BTIG Research repeating the rating for TCRX by listing it as a “Buy.” The predicted price for TCRX in the upcoming period, according to BTIG Research is $12 based on the research report published on May 16, 2024 of the previous year 2024.
Needham, on the other hand, stated in their research note that they expect to see TCRX reach a price target of $11. The rating they have provided for TCRX stocks is “Buy” according to the report published on May 13th, 2024.
Wedbush gave a rating of “Outperform” to TCRX, setting the target price at $8 in the report published on June 22nd of the previous year.
TCRX Trading at -0.02% from the 50-Day Moving Average
After a stumble in the market that brought TCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.50% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TCRX starting from Lynx1 Capital Management LP, who purchase 1,388,794 shares at the price of $1.20 back on May 19 ’25. After this action, Lynx1 Capital Management LP now owns 6,746,141 shares of Tscan Therapeutics Inc, valued at $1,666,553 using the latest closing price.
Lynx1 Capital Management LP, the 10% Owner of Tscan Therapeutics Inc, purchase 1,200,000 shares at $1.20 during a trade that took place back on May 20 ’25, which means that Lynx1 Capital Management LP is holding 7,946,141 shares at $1,440,000 based on the most recent closing price.
Stock Fundamentals for TCRX
Current profitability levels for the company are sitting at:
- -31.6 for the present operating margin
- 0.59 for the gross margin
The net margin for Tscan Therapeutics Inc stands at -29.74. The total capital return value is set at -0.46. Equity return is now at value -78.93, with -45.85 for asset returns.
Based on Tscan Therapeutics Inc (TCRX), the company’s capital structure generated 0.32 points at debt to capital in total, while cash flow to debt ratio is standing at -1.23. The debt to equity ratio resting at 0.46. The interest coverage ratio of the stock is -41.42.
Currently, EBITDA for the company is -119.74 million with net debt to EBITDA at 0.45. When we switch over and look at the enterprise to sales, we see a ratio of 5.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.55.
Conclusion
In a nutshell, Tscan Therapeutics Inc (TCRX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
